Synonym
Seclazone; W-2354; W 2354; W2354; W 2352;
IUPAC/Chemical Name
2H,9H-Isoxazolo(3,2-b)(1,3)benzoxazin-9-one, 3,3a-dihydro-7-chloro-
InChi Key
XWXVKXXKKLBDDJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H8ClNO3/c11-6-1-2-8-7(5-6)10(13)12-9(15-8)3-4-14-12/h1-2,5,9H,3-4H2
SMILES Code
O=C1N(OCC2)C2OC3=CC=C(Cl)C=C13
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
225.63
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Viaje A, Slaga TJ, Wigler M, Weinstein IB. Effects of antiinflammatory agents on mouse skin tumor promotion, epidermal DNA synthesis, phorbol ester-induced cellular proliferation, and production of plasminogen activator. Cancer Res. 1977 May;37(5):1530-6. PubMed PMID: 856468.
2: Slaga TJ, Viaje A, Bracken W. The effects of anti-inflammatory agents on skin tumor initiation and aryl hydrocarbon hydroxylase. Res Commun Chem Pathol Pharmacol. 1977 Feb;16(2):337-50. PubMed PMID: 847288.
3: Edelson J, Schuster EB, Douglas JF. Optimal conditions for the hydrolysis of seclazone by rat hepatic microsomes. Arch Int Pharmacodyn Ther. 1974 Sep;211(1):99-106. PubMed PMID: 4218724.
4: Edelson J, Schuster E, Shahinian S, Douglas JF. The metabolic fate of seclazone in man. Arch Int Pharmacodyn Ther. 1974 May;209(1):66-74. PubMed PMID: 4416360.
5: Edelson J, Douglas JF, Ludwig BJ. Seclazone: biotransformation during absorption in the rat, binding in plasma, and disappearance from plasma in the dog. Drug Metab Dispos. 1973 Nov-Dec;1(6):737-41. PubMed PMID: 4156294.
6: Edelson J, Douglas JF, Ludwig BJ. Absorption, distribution, and metabolic fate of seclazone (7-chloro-3,3a-dihydro-2H,9H-isoxazolo(3,2-b) (1,3)benzoxazin-9-one). J Pharm Sci. 1973 Feb;62(2):229-32. PubMed PMID: 4631323.
7: Edelson J, Douglas JF. Measurement of gastrointestinal blood loss in the rat: the effect of aspirn, phenylbutazone and seclazone. J Pharmacol Exp Ther. 1973 Feb;184(2):449-52. PubMed PMID: 4540048.
8: Hrdina PD, Ling GM. The in vivo antibradykinin activity of seclazone (7-chloro-3,3a-dihydro-2H,9H-isoxazolo(3,2-b) (1,3)benzoxazin-9-one), a new anti-inflammatory agent. Pharmacology. 1973;10(3):136-42. PubMed PMID: 4761775.
9: Berger FM, Bates HM, Diamantis W, Kletzkin M, Plekss OJ, Sofia RD, Spencer HJ. The pharmacological properties of seclazone (7-chloro-3,3a-dihydro-2H, 9H-isoxazolo (3,2-b) (1,3) benzoxazin-9-one) a new anti-inflammatory agent. Pharmacology. 1973;9(3):164-76. PubMed PMID: 4714232.